Direct Ras G12C inhibitors: crossing the rubicon
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Cancer"
DOI: 10.1038/s41416-019-0499-1
Abstract: SummaryDespite its status as the most commonly mutated oncogene in cancer, Ras has long been considered ‘undruggable’. In 2019, we will see the first clinical trial results for direct mutant Ras inhibitors, a result of persistent… read more here.
Keywords: crossing rubicon; direct ras; g12c inhibitors; inhibitors crossing ... See more keywords
Abstract 1079: Combination of tipifarnib with KRAS G12C inhibitors to prevent adaptive resistance
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1079
Abstract: Selective KRAS G12C inhibitors, including AMG510 (sotorasib) and MRTX849 (adagrasib), have exhibited clinical activity in patients with non-small cell lung cancer (NSCLC); however, drug resistance and relapse inevitably occur through various mechanisms, which limits the… read more here.
Keywords: kras g12c; g12c inhibitors; adaptive resistance; combination ... See more keywords
Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.793121
Abstract: Approximately 20% of lung adenocarcinomas harbor KRAS mutations, an oncogene that drives tumorigenesis and has the ability to alter the immune system and the tumor immune microenvironment. While KRAS was considered “undruggable” for decades, specific… read more here.
Keywords: kras g12c; g12c inhibitors; immune regulatory; lung ... See more keywords
Targeting KRAS in PDAC: A New Way to Cure It?
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14204982
Abstract: Simple Summary Pancreatic cancer is one of the most intractable malignant tumors worldwide, and is known for its refractory and poor prognosis. Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. KRAS… read more here.
Keywords: g12c inhibitors; pancreatic cancer; kras pdac; targeting kras ... See more keywords